Heuking advises 4basebio on takeover bid by Sparta AG

A Heuking team led by capital markets expert Dr. Thorsten Kutheadvised 4basebio AG on a takeover bid by Sparta AG. Sparta AG issued a voluntary public takeover offer to all 4basebio shareholders to buy their shares at EUR 2.00 per share.

4basebio AG with its registered office in Heidelberg through their technologies and products enables advances in medical science and patient care focusing on technologies and products centered around DNA. After divestment of its immunology and proteomics products portfolio, on January 1 2020, the Company, formerly operating under the name of Expedeon AG, changed its name to 4basebio AG. The Heuking team led by Dr. Kuthe has been advising 4basebio AG for several years, recently on the sale of its immunology and proteomics products portfolio to Abcam.

Sparta AG with its registered office in Heidelberg is an investment company focusing on investment in listed companies within the German speaking area for a time of up to five years.

Counsel to 4basebio AG
Heuking Kühn Lüer Wojtek:
Dr. Thorsten Kuthe (lead, capital markets law), Cologne
Meike Dresler-Lenz
Stefan Westerheide, LL.M. oec
Dr. Gero Lingen
Lena Pfeufer (all capital markets law), all Cologne
Michael Neises (capital markets law), Frankfurt